Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.
If you do choose to short, best close it before April and the likely EUA.
People using vaccines to deramp the share is so 2020 :)
Strange game Leicester were poor throughout yet got lucky with VAR doing lines wrong (again) and a mad collison between goalie and CB.
The first volunteer enrolled in the SNG001 sub-study on February 10. The other agents under study are expected to begin enrolling participants soon.
**
Thats the best bit SNG001 already dosing the other 3 candidates have yet to start :) We take an early lead :)
Can you bore off with your cross ramps
China have just banned BBC news from being aired in the country.
Must have really been annoyed at inhaled interferon being misrepresented
BBC are government propaganda and should be largely ignored when it comes to Covid :)
Cool fact
Janet Wood**** was Director of the Office of Therapeutics Research and Review (1992–1994), Wood**** covered the approval of the first biotechnology-based treatments for multiple sclerosis and cystic fibrosis.
Betaseron - interferon beta was that treatment
so Janet has form approving interferon beta as a treatment so as acting FDA chief can only bode well :)
This was posted apund a week ago or so
The Royal Bournemouth Hospital is participating in SPRINTER (SG018) a placebo-controlled phase III trial of SNG001 who are hospitalised due to COVID-19 and require standard oxygen therapy. 1 patient has been enrolled so far.
https://www.rbch.nhs.uk/index.php?id=2974
https://www.nature.com/articles/s41586-021-03324-6#article-info
New peer reviewed nature article on mrna vaccines. Expect more mutations and vaccines will need to be updated to counter virus evolution.
'Here we report on the antibody and memory B cell responses in a cohort of 20 volunteers who received either the Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines1–4. Eight weeks after the second vaccine injection volunteers showed high levels of IgM, and IgG anti-SARS-CoV-2 spike protein (S) and receptor binding domain (RBD) binding titers. Moreover, the plasma neutralizing activity, and the relative numbers of RBD-specific memory B cells were equivalent to individuals who recovered from natural infection5,6. However, activity against SARS-CoV-2 variants encoding E484K or N501Y or the K417N:E484K:N501Y combination was reduced by a small but significant margin. Vaccine-elicited monoclonal antibodies (mAbs) potently neutralize SARS-CoV-2, targeting a number of different RBD epitopes in common with mAbs isolated from infected donors5–8. However, neutralization by 14 of the 17 most potent mAbs tested was reduced or abolished by either K417N, or E484K, or N501Y mutations. Notably, the same mutations were selected when recombinant vesicular stomatitis virus (rVSV)/SARS-CoV-2 S was cultured in the presence of the vaccine elicited mAbs. Taken together the results suggest that the monoclonal antibodies in clinical use should be tested against newly arising variants, and that mRNA vaccines may need to be updated periodically to avoid potential loss of clinical efficacy.'
Oh nos you said the word imminent :)
https://www.medrxiv.org/content/10.1101/2021.02.04.21251134v1
There is the trial design and some of the headline information on Budesonide.
Yes just read the email looks really good to me.
Sharing your experience of using SNG001 at home and how easy it was to do should be a big positive. I also like the activ-2 and the potential the treatment can be nicked by the USA :)
More vaccine vaccine vaccine.
I remember with this drug that there was a whistleblower Dr who claims it is mutagenic. No doubt powerful antiviral but has some 'baggage' it needs to sort out I suspect.
budesonide reduced relative risk of requiring urgent care or hospitalisation by 90% in 28-day study period sounds good. However we need some more data as 'urgent care' may just mean someone calling 111. The results wouldn't look as great if it said -
budesonide reduced relative risk of calling 111 by 90% in 28-day study period.
So need a breakdown of this data of who actually went to hospital or who went to walk in centre/called 111. I couldnt see it.
The other issue is the trial wasn't blinded and was an open label trial so the patients and researcher knew they were taking the drug or on SOC. They were then asked to fill out a questionnaire to get results. This obviously will influence results.
To clarify I should say this was based on human lung-only mice (LoM) :)
Thanks Borsaci06. This is Mercks new antiviral, probably SNGs biggest 'competitor'
This is an in vivo study, ie how the drug performs in the human lung and results looks to be very good at early stage. So looks like a real deal. However the surprise in this study is what could be the cause of such stellar results.
'Notably, numerous interferon-stimulated genes (ISGs) and inflammatory cytokine genes, including pro-inflammatory cytokines genes IL6, CXCL8 (IL-8), CXCL10(IP-10), TNF, and CCL5 (RANTES) were potently induced in infected lung tissue (Supplementary Tables 1 and 2). We also observed dramatic upregulation of IFNB1, IFNL1, IFNL2, and IFNL3 expression (>1,000 fold for all) at 2 days post-exposure, suggesting that these cytokines play a key role in the antiviral response to SARS-CoV-2 (Supplementary Tables 1 and 2). Gene set enrichment analysis (GSEA) showed over 840 gene pathways significantly upregulated (p<0.05) including response to type 1 interferon (p=0.0011), response to virus (p=0.0010), innate immune response (p=0.0010), cytokine mediated signaling (p=0.0010), cytokine production (p=0.0010)'
We observed robust induction of IFNB1 expression during acute infection followed by a decline in expression. Interestingly, an analysis of post-mortem COVID-19 patient lungs5 did not reveal increased IFNB1 expression and it has been shown in vitro that its expression is blocked during SARS-CoV infection31,32. These results suggest that in human lung tissue IFNB1 expression is induced during acute SARS-CoV-2 infection. While this study was not designed to evaluate the effect of type I IFN on SARS-CoV-2 replication in vivo, in vitro studies and in vivo mousestudies showed that type I IFN treatment restricts SARS-CoV-2 replication7,33.
The data I have seen is not from a site like simplywallstreet its from a very good source, I would need permission to divulge anything further.
Some members of the reddit board can confirm the findings.
'He also alluded to a key challenge in the administration of antivirals, which is portability. Access is a profound challenge in primary care for the delivery of antivirals, and that is one of the issues we have to resolve.'
This sentence refers to antivirals in general and the issue of portability ie using them at home or primary care settings. Not directed at SNG directly per se. No point having an efficacious treatment that can't be used at home by the patient. We have seen this in the USA very little takeup of mAbs treatments for primary care/home use.
Portability is an issue for the majority of mAbs treatments as they require trained medical staff on site and require IV plus very expensive. Hence not very suitable :0
SNG001 is portable, the home trial has proven this which Richard and Stephen have alluded to. Box gets delivered to your door with instructions and a zoom call or phone call if required by a nurse.
People are looking at this in the wrong light IMO, Lord Winston and Lord Bethell are indirectly highlighting an advantage of SNG over other treatments.